| |
See how this AI-powered solution provided the sponsor a real-time competitive landscape evaluation for Immuno-oncology therapies with valuable insights for enhanced decision-making. Read the case study. 
|
|
|
Wednesday, September 6, 2023 | 2:00 PM ET / 11:00 AM PT Attendees will learn about the latest tools for interacting with medical images, how to guide readers through labeling workflows, and streamlining adjudication and data standardization. Discussions will include real-world use cases of how pharma companies are enhancing AI development by optimizing reader workflows. Register now. 
|
|
| By Nick Paul Taylor It’s all change at AstraZeneca. The Anglo-Swedish drugmaker not only revealed its second quarter earnings results, but also disclosed the elimination of several pipeline programs, the purchase of a portfolio of preclinical gene therapies from Pfizer and the upcoming departure of a key, long-serving R&D executive. |
|
|
|
| Philadelphia, PA |  |
|
|
By Kevin Dunleavy Biogen has revealed a proposal to acquire Reata Pharmaceuticals for $7.3 billion. The Texas-based rare disease specialist brings newly approved Skyclarys, the first treatment for the neurologic disorder Friedreich’s ataxia with peak sales potential of $1.5 billion. |
By Helen Floersh Researchers from City of Hope have pinned down the mechanism behind an oral chemotherapy that is already being tested in humans, adding weight to the preclinical package of data underpinning the drug's potential in a range of solid tumors. |
By Fraiser Kansteiner Paxlovid generated just $143 million in worldwide sales for the second quarter, while mRNA vaccine Comirnaty brought home $1.4 billion. Against that backdrop, Pfizer reported total second quarter revenues of $12.7 billion, down a whopping 53% operationally from the same period last year. |
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now. 
|
|
By Nick Paul Taylor Pfizer is ringing the changes as it exits the second quarter, tossing out a midstage pneumococcal vaccine candidate and a handful of phase 1 assets including a respiratory syncytial virus prospect it picked up in last year’s ReViral takeover. |
By Max Bayer The FDA's Peter Marks, M.D., Ph.D., thinks gene editing—specifically base editing—could be a "game changer," but progress has been slow, likely due to discouragement with the regulatory process. |
By Kevin Dunleavy Merck’s $10.8 billion acquisition of Prometheus Biosciences earlier this year gave the New Jersey company increased diversity in its portfolio, much needed considering its overwhelming dependence on cancer juggernaut Keytruda. But buying out the San Diego immunology specialist has not satisfied Merck’s appetite for M&A, executives said. |
By Conor Hale Listed for sale on the clinical testing giant's website, the AD-Detect beta amyloid test retails for $399. |
By Nick Paul Taylor Lundbeck and Otsuka are ramping up their pursuit of an Alzheimer’s disease niche. Months after winning an FDA nod for Rexulti in dementia-related agitation, the partners have launched an ad to let children of Alzheimer’s patients know a new treatment option is available. |
By Joseph Keenan Lupin Pharmaceuticals, the U.S. unit of India’s Lupin Limited, issued a voluntary recall of two lots of birth control pills due to the potential that they may not be effective in preventing pregnancy. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss how to support patients during the cancer drug shortage, plus this week's headlines. |
|
|---|
|
|
|
Ready to take your marketing to the next level? Attend Digital Pharma East: The premier marketing event for the life sciences community, taking place Sept 11-14 in Philadelphia.Join Us Today! .png)
|
|
Whitepaper Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Webinar Watch this webinar to learn how an end-to-end platform can simplify the systems landscape and help facilitate cross-functional collaboration, accelerate clinical development and centralize data for efficacious decision-making. Sponsored by: Cognizant |
Paid Marketplace New commercial models and resources address unique challenges associated with commercializing complex therapies. Sponsored by: EVERSANA |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
Whitepaper Best practices from biopharma clinical studies for medical device manufacturers around the efficient collection and use of data to speed insights into product safety and efficacy Sponsored by: Cognizant |
| |
|
